Poll

Poll: What do you consider the optimal approach for treating high-risk prostate cancer?

External beam RT with androgen deprivation therapy
Radical prostatectomy with pelvic lymph node dissection
Neoadjuvant treatment with chemotherapy or ADT
Other
Not sure

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, answers a question during a Zoom video interview
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Post-RP incontinence: Low procedure rates examined
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Related Content
Patient talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke
“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC
July 9th 2025

FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

Benjamin P. Saylor Hannah Clarke
The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Expanded indication sought for niraparib plus AAP in Europe
July 7th 2025

Expanded indication sought for niraparib plus AAP in Europe

Hannah Clarke
The application is supported by data from the phase 3 AMPLITUDE trial.
Regulatory recap: FDA approvals in urology from the first half of 2025
July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke
Take a look through all the regulatory milestones in urology from the first half of the 2025.
© 2025 MJH Life Sciences

All rights reserved.